40 related articles for article (PubMed ID: 27647449)
1. Codelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cells.
Gong Z; Chen D; Xie F; Liu J; Zhang H; Zou H; Yu Y; Chen Y; Sun Z; Wang X; Zhang H; Zhang G; Yin C; Gao J; Zhong Y; Lu Y
Nanomedicine (Lond); 2016 Oct; 11(19):2565-2579. PubMed ID: 27647449
[TBL] [Abstract][Full Text] [Related]
2. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
3. Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin.
Borlle L; Dergham A; Wund Z; Zumbo B; Southard T; Hume KR
BMC Vet Res; 2019 Jan; 15(1):36. PubMed ID: 30678671
[TBL] [Abstract][Full Text] [Related]
4. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell.
Lee HG; Shin SJ; Chung HW; Kwon SH; Cha SD; Lee JE; Cho CH
J Gynecol Oncol; 2017 Mar; 28(2):e14. PubMed ID: 27894167
[TBL] [Abstract][Full Text] [Related]
5. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133
Klose J; Eissele J; Volz C; Schmitt S; Ritter A; Ying S; Schmidt T; Heger U; Schneider M; Ulrich A
BMC Cancer; 2016 Nov; 16(1):896. PubMed ID: 27855654
[TBL] [Abstract][Full Text] [Related]
6. Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression.
Ko JC; Zheng HY; Chen WC; Peng YS; Wu CH; Wei CL; Chen JC; Lin YW
Biochem Pharmacol; 2016 Dec; 122():90-98. PubMed ID: 27666600
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cells.
Wang M; Xie F; Wen X; Chen H; Zhang H; Liu J; Zhang H; Zou H; Yu Y; Chen Y; Sun Z; Wang X; Zhang G; Yin C; Sun D; Gao J; Jiang B; Zhong Y; Lu Y
Nanomedicine (Lond); 2017 May; 12(9):1025-1042. PubMed ID: 28440698
[TBL] [Abstract][Full Text] [Related]
8. Advances of nanotechnology applied to cancer stem cells.
Yue M; Guo T; Nie DY; Zhu YX; Lin M
World J Stem Cells; 2023 Jun; 15(6):514-529. PubMed ID: 37424953
[TBL] [Abstract][Full Text] [Related]
9. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.
Mahmoud K; Swidan S; El-Nabarawi M; Teaima M
J Nanobiotechnology; 2022 Mar; 20(1):109. PubMed ID: 35248080
[TBL] [Abstract][Full Text] [Related]
10. Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy.
Tefas LR; Barbălată C; Tefas C; Tomuță I
Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452081
[TBL] [Abstract][Full Text] [Related]
11. Salinomycin-Loaded Small-Molecule Nanoprodrugs Enhance Anticancer Activity in Hepatocellular Carcinoma.
Wang J; Zhuo J; Tao Y; Xu S; Chen Z; Yang F; Ke Q; Xie H; Zheng S; Wang H; Xu X
Int J Nanomedicine; 2020; 15():6839-6854. PubMed ID: 32982236
[TBL] [Abstract][Full Text] [Related]
12. Nanoliposomes as a Therapeutic Tool for Alzheimer's Disease.
Ordóñez-Gutiérrez L; Wandosell F
Front Synaptic Neurosci; 2020; 12():20. PubMed ID: 32523525
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-responsive highly biocompatible nanodroplets loaded with doxorubicin for tumor imaging and treatment
Zhou X; Guo L; Shi D; Meng D; Sun X; Shang M; Liu X; Zhao Y; Li J
Drug Deliv; 2020 Dec; 27(1):469-481. PubMed ID: 32166985
[TBL] [Abstract][Full Text] [Related]
14. Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles.
Gao J; Liu J; Xie F; Lu Y; Yin C; Shen X
Int J Nanomedicine; 2019; 14():9199-9216. PubMed ID: 32063706
[TBL] [Abstract][Full Text] [Related]
15. Dual-targeting nanomicelles with CD133 and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancer-initiating cells.
Huang X; Wan J; Leng D; Zhang Y; Yang S
Exp Ther Med; 2020 Jan; 19(1):192-204. PubMed ID: 31853290
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development.
Feng J; Byrne NM; Al Jamal W; Coulter JA
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31835751
[TBL] [Abstract][Full Text] [Related]
17. Enhanced targeting of prostate cancer-initiating cells by salinomycin-encapsulated lipid-PLGA nanoparticles linked with CD44 antibodies.
Wei J; Sun J; Liu Y
Oncol Lett; 2019 Apr; 17(4):4024-4033. PubMed ID: 30930999
[TBL] [Abstract][Full Text] [Related]
18. Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers.
Das M; Huang L
J Pharmacol Exp Ther; 2019 Sep; 370(3):647-656. PubMed ID: 30541917
[TBL] [Abstract][Full Text] [Related]
19. Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.
Chen D; Pan X; Xie F; Lu Y; Zou H; Yin C; Zhang Y; Gao J
Int J Nanomedicine; 2018; 13():6855-6870. PubMed ID: 30498347
[TBL] [Abstract][Full Text] [Related]
20. Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers.
Kaushik V; Yakisich JS; Kumar A; Azad N; Iyer AKV
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30262730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
